What Researchers Did
Researchers conducted a trial to see if hyperbaric oxygen therapy, given as six sessions at 2.4 atmospheres absolute (ATA) with antibiotics, was safe and possible for selected patients with left-sided infective endocarditis caused by Gram-positive bacteria.
What They Found
Out of 13 included patients, 10 (77%) completed the hyperbaric oxygen therapy, and no serious side effects were reported. Blood tests showed significant changes in biomarkers, including a reduction in CRP levels (from 22 to 15 mmol/L) and activated platelets, suggesting potential immune system modulation.
Canadian Relevance
No direct Canadian connection identified. Infective endocarditis is not a Health Canada-recognized indication for hyperbaric oxygen therapy.
Study Limitations
This study was a small, open-label feasibility and safety trial, meaning it did not assess the clinical effectiveness of hyperbaric oxygen therapy for infective endocarditis.